Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07024316 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

Study acronym: ATL001-PII-CEP
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 1, 2027 to May 1, 2028
    • Study completion date: Nov 1, 2027 to Jun 1, 2028
    • Start date changed from estimate of Jan 15, 2026 to Jan 29, 2026
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Nov 1, 2025 to Jan 15, 2026
    • Primary completion date: Aug 1, 2027 to Oct 1, 2027
    • Study completion date: Sep 1, 2027 to Nov 1, 2027
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD
Trial Details
NCT Number NCT07024316
Lead Sponsor Atlas Molecular Pharma
Conditions
(from sponsor)		 Congenital Erythropoietic Porphyria (CEP)
Related terms Porphyria, Erythropoietic
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov